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Background: With the prospect of increasing prevalence of cancer, the issue of multiple primary cancers becomes
more relevant. The aim of this study was to estimate the risk of developing a tobacco-related subsequent primary
cancer (TRSPC) in persons with a tobacco-related first primary cancer (TRFPC) compared with the general
population in Bavaria, Germany.
Methods: Using data from the Population-Based Cancer Registry Bavaria, we analyzed TRFPC and TRSPC diagnosed
in Bavaria between 2002 and 2008 to estimate the relative and absolute risk of developing TRSPC using
standardized incidence ratios (SIR) and excess absolute risks (EAR).
Results: 121,631 TRFPC in men and 75,886 respective cancers in women were registered, which in 2.5% of male
and 1.2% of female cancer patients were followed by at least one TRSPC. In both males and females, the highest
increased risks compared to the general population were found within the group of cancer in the mouth/pharynx,
oesophagus, larynx, and lung/bronchus.
Conclusions: With respect to cancer in the mouth/pharynx, oesophagus, larynx, lung/bronchus, kidney, urinary
bladder and urinary tract, smoking was confirmed as a shared risk factor based on our finding of mutually
significantly increased risks of TRSPC. The results of this study illustrate the importance of smoking cessation and of
continued follow-up care especially of smokers with the aforementioned TRFPC to detect TRSPC at an early stage.Background
Probably due in part to technological advances in the
early detection and treatment of cancer, the prevalence
of cancer in Germany is rising [1]. Therefore, interest
has increased with regard to the risk of developing sub-
sequent primary cancers in cancer survivors.
Tobacco smoking is one of the most easily preventable
risk factors for cancer. It is responsible for about 20% of
all cancer deaths in Germany [2]. In view of the public
health-relevance of tobacco-related cancer, it is import-
ant to estimate the burden of tobacco-related subse-
quent primary cancer (TRSPC) among persons with
tobacco-related first primary cancer (TRFPC).
Therefore, in this population-based study, we analyzed
tobacco-related cancers. According to Schottenfeld [3],
this group includes cancer of the mouth and pharynx,
oesophagus, stomach, colon and rectum, pancreas, lar-
ynx, lungs and bronchus, kidneys, urinary tract, urinary* Correspondence: Martin.Radespiel-Troeger@ekr.med.uni-erlangen.de
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reproduction in any medium, provided the orbladder, respectively, and leukemia. For malignancies in
the mouth/pharynx, oesophagus, pancreas, larynx, lung/
bronchus, kidney, urinary tract, and urinary bladder,
tobacco smoking is considered as a main risk factor. For
malignancies in the stomach, colon/rectum as well as for
leukemia, a weaker but positive association with tobacco
smoking is known or at least suspected [3].
With regard to the aforementioned malignancies, the
aim of this study was to estimate the risk of developing
TRSPC among persons with TRFPC compared with the
general population, and to test the etiologic hypothesis
that the risk of TRSPC is significantly increased among
persons with TRFPC because of the shared risk factor
tobacco smoking. Furthermore, based on our results, it
may be possible to obtain new insights into the etiology
of the evaluated cancer types.Methods
In the federal state of Bavaria, located in the southeast of
Germany, population-based cancer registration com-
menced in 1998, and full-scale registration covering aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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doctors, dentists, pathologists, and local health authorities
are asked to send notifications about all types of newly
diagnosed cancer to their respective regional cancer centre
where they are collected. Notifications are forwarded to
the confidentiality office of the Bavarian cancer registry in
Nuremberg for the purpose of data checking and pseudo-
nymization. All pseudonymized notifications are sent to
the Bavarian cancer registration office in Erlangen where
they are linked by means of stochastic record linkage [4],
stored permanently, and analysed.
In this study we analyzed TRFPC and TRSPC diag-
nosed in Bavaria between 2002 and 2008 in persons aged
15 years or older, utilizing data from the Population
Based Cancer Registry Bavaria. Cases of childhood cancer
were excluded from the evaluation because of the differ-
ent classification of childhood cancer [5]. DCO (death
certificate only) cases were included in these analyses.
The date of diagnosis was defined by the month and
year of the diagnosis because the day of diagnosis is not
recorded in this registry. Using the methodology pro-
posed by Schoenberg and Myers [6], 2,934 patients
(1.5%) were excluded from the evaluation because the
diagnoses of TRFPC and TRSPC, respectively, were
made at the same date. After this exclusion, 121,631
TRFPC in men and 75,886 respective cancers in women
were included in the analysis.
Cancer diagnoses were coded according to the Inter-
national Classification of Diseases 10th Revision (ICD-
10) [7].
We report on the risk of TRSPC among persons with
TRFPC compared with the general population. This
group includes cancer in the mouth/pharynx (ICD-10:
C00-C14), oesophagus (C15), stomach (C16), colon/rec-
tum (C18-C21), pancreas (C25), larynx (C32), bronchus/
lung (C33-C34), kidney (C64), urinary tract (C65-C66,
C68), and the urinary bladder (C67, D09.0, D41.4), re-
spectively, and leukemia (C91-C95) [3].
Except for the diagnosis group of the urinary bladder
(C67, D09.0, D41.4), only invasive carcinomas were
examined in accordance with published guidelines of
cancer registration [8]. In the urinary bladder, only the
first diagnosed urinary bladder tumour was counted re-
gardless of its invasiveness [8].
A commonly used estimator for the relative risk of a
subsequent primary cancer among cancer patients com-
pared with the general population is the standardized in-
cidence ratio (SIR) calculated according to Schoenberg
and Myers [6], which compares the number of observed
cases with the expected number of cases calculated
according to the method of indirect standardization by
taking into account the different age distributions in the
study population and in the reference population, re-
spectively [9], and the year of diagnosis.In order to estimate the risk of TRSPC, we need to
calculate the individual times at risk (person-years at
risk, PY) of developing a subsequent malignancy among
cancer patients with a TRFPC. The individual PY were
calculated as the time from the diagnosis of the first can-
cer until the date of death or December 2008, whichever
occurred first.
Data were stratified by sex, site of first primary cancer,
site of subsequent primary cancer, 5-year age groups,
and calendar year. The expected number of subsequent
primary cancers in each stratum was obtained by multi-
plying the sex-, site-, age-, and calendar year-specific in-
cidence rates (rates per person-year) by the related
person-years at risk. These cases were then added up for
all age groups and calendar years to obtain the total
number of expected cases at each site for each sex.
The exact 95% confidence interval (95% CI) of the SIR
was calculated according to Garwood [10] assuming a
Poisson distribution of the observed number of cases.
This method is also suggested by Sahai et al. [11] and
SEER [12]. An increased or decreased risk is considered
to be statistically significant if the associated confidence
interval does not include the value one.
The SIR is commonly used to test etiologic hypoth-
eses, e.g. the hypothesis of a significantly increased risk
of TRSPC among persons with TRFPC. In this context,
the hypothesis of a risk factor shared between two ma-
lignancies may be confirmed if the risk is mutually and
significantly increased, that is, if both tumour A after
tumour B and tumour B after tumour A show a signifi-
cantly increased risk of subsequent malignancy among
cancer patients compared to the general population [13].
A second useful measure is the excess absolute risk
(EAR), which is computed by subtracting the number of
expected cases from the number observed cases, divid-
ing this difference by the sum of observed person-years
and then multiplying by 10,000 to obtain the excess of
cases in cancer patients compared with the general refer-
ence population per 10,000 person-years [13,14]. The
EAR is often used to measure the burden of a specific
subsequent primary cancer in the population of defined
cancer patients. It is reported in this paper in addition to
the SIR for each first and subsequent site of cancer
according to sex.
The SIR and EAR provide different information about
the risk of developing subsequent malignancies among
cancer patients compared with the general population
and therefore complement each other. For example, in
rare tumours, it may happen that there are three
observed cases of a specific subsequent cancer in a
defined cancer population but only one expected case.
In this case, the SIR would show a threefold risk increase
while the absolute excess would be only 2 cases, which
would result in a low EAR. This example demonstrates
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follow-up examinations among cancer patients be-
cause it provides information on the relative usefulness
of these examinations compared to other possible
interventions.
Because all personal data were pseudonymised prior to
analysis and only aggregated results are published, no
ethical review committee approval was required for the
purpose of the present observational study which was
performed in compliance with the Declaration of Hel-
sinki [15].
All analyses were conducted using a self-programmed
software written in the statistical programming language
R [16].Results
During the follow-up period (median, 1.0/0.8 years in
men/women), 3,097 (2.5%) male and 924 (1.2%) female
cancer patients experienced at least one TRSPC.
In Table 1, the numbers of included patients, their me-
dian age at diagnosis of first primary cancer, their total
and their median person-years at risk are given according
to sex and site of TRFPC, respectively. Except for pancre-
atic cancer, the number of patients was greater in men
than in women. The median age at diagnosis of first pri-
mary cancer was higher in women than in men, except
for cancer in the larynx and lung/bronchus. The median
follow-up times were similar among men and women.
The relative and absolute risks of TRSPC are given in
Table 2 according to sex and type of TRFPC and
TRSPC, respectively.Table 1 Patient characteristics (number of persons, total pers
age at diagnosis of first primary cancer, and median person-y
site of first tobacco-related primary cancer and sex; Bavaria;
Men
Site of first primary cancer n Median age Sum PY
mouth and pharynx 8,579 60 17,901
oesophagus 4,084 65 4,759
stomach 9,613 72 12,593
colon and rectum 34,663 70 74,122
pancreas 6,961 70 4,183
larynx 2,916 64 6,989
bronchus and lung 25,733 69 22,923
kidney 7,760 67 17,985
urinary tract 1,135 73 1,923
urinary bladder 14,726 72 35,950
leukemia 5,461 69 9,116
all cancer sites combined 121,631 69 208,444
n, number of persons; median age, median age at diagnosis of first primary cancer;
years at risk of subsequent primary cancer; median PY, median person-years at riskWe found considerable differences between men and
women in view of the magnitude of the estimated rela-
tive and absolute risk of TRSPC.
With regard to first primary cancers in mouth/phar-
ynx, oesophagus, larynx and urinary tract, SIRs were
considerably higher in women than in men, whereas in
about half of these analyses, the corresponding EAR was
lower in women than in men. The largest SIR was
observed in women with subsequent primary cancer
(SPC) in the larynx after first primary cancer (FPC) in
the mouth/pharynx (SIR, 69.05; O = 7), whereas the cor-
responding SIR among men was only 14.10 (O= 43).
The corresponding EAR, however, in men (22 cases per
10,000 person years) was about twice as high as in
women. Among men, the largest relative risk was found
with SPC in the oesophagus after FPC in mouth/pharynx
(SIR, 19.63). The largest absolute risk, however, was
observed among men for SPC in the lung/bronchus after
FPC in the mouth/pharynx (EAR, 98.1) and among
women for SPC in the lung/bronchus after FPC in the
larynx (EAR, 102.9).
Based on the presented results, we found five groups
of TRFPC with mutually and significantly increased risk
of TRSPC each of which was identified among at least
one sex, and which are presented in Table 3 by splitting
the groups into dyads. Furthermore, known shared risk
factor(s) are reported.
Group 1 contained malignancies in the mouth/pharynx
(C00-C14), oesophagus (C15), larynx (C32), and lung/
bronchus (C33-C34). However, all pairwise associations
within this group revealed a mutually significantly
increased risk only among men. Among women, mutuallyon-years at risk of subsequent primary cancer, median
ears at risk of subsequent primary cancer according to
2002 – 2008)
Women
Median PY n Median age Sum PY Median PY
1.4 2,673 64 5,942 1.7
0.6 959 70 983 0.5
0.6 7,896 78 9,810 0.5
1.7 29,262 75 58,642 1.4
0.3 7,364 76 3,992 0.2
1.9 356 63 829 1.8
0.3 11,087 68 11,301 0.5
1.8 5,192 72 11,581 1.8
1.0 795 76 1,429 1.2
2.0 5,654 76 12,241 1.5
0.8 4,648 74 6,565 0.3
1.0 75,886 74 123,315 0.8
PY, person-years at risk of subsequent primary cancer; sum PY, total person-
of subsequent primary cancer.
Table 2 Relative and absolute risks of subsequent tobacco-related primary cancer according to type of first tobacco-






O SIR (95% CI) EAR O SIR (95% CI) EAR
mouth, pharynx oesophagus 86 19.63 (15.71-24.25) 45.6 15 48.06 (26.9-79.27) 24.7
stomach 24 2.87 (1.84-4.27) 8.7 2 0.93 (0.11-3.35) −0.3
colon, rectum 54 1.65 (1.24-2.15) 11.9 12 1.42 (0.74-2.49) 6.0
pancreas 9 1.36 (0.62-2.58) 1.3 2 0.92 (0.11-3.31) −0.3
larynx 43 14.10 (10.21-18.99) 22.3 7 69.05 (27.76-142.26) 11.6
bronchus, lung 201 7.90 (6.85-9.07) 98.1 42 12.36 (8.91-16.71) 65.0
kidney 17 2.11 (1.23-3.38) 5.0 2 1.27 (0.15-4.60) 0.7
urinary tract 3 2.82 (0.58-8.24) 1.1 - - -
urinary bladder 18 1.28 (0.76-2.02) 2.2 2 1.18 (0.14-4.28) 0.5
leukemia 14 3.03 (1.66-5.09) 5.2 2 1.59 (0.19-5.75) 1.25
oesophagus mouth, pharynx 36 14.18 (9.93-19.64) 70.3 5 34.92 (11.34-81.48) 49.4
stomach 5 1.64 (0.53-3.82) 4.1 1 2.41 (0.06-13.42) 6.0
colon, rectum 23 1.99 (1.26-2.98) 24.0 6 3.70 (1.36-8.05) 44.5
pancreas 5 2.15 (0.70-5.01) 5.6 2 4.71 (0.57-17.00) 16.0
larynx 7 7.44 (2.99-15.33) 12.7 - - -
bronchus, lung 23 2.62 (1.66-3.92) 29.9 6 9.42 (3.46-20.50) 54.5
kidney 8 2.97 (1.28-5.86) 11.2 2 6.54 (0.79-23.62) 17.2
urinary tract 1 2.53 (0.06-14.12) 1.3 - - -
urinary bladder 12 2.34 (1.21-4.09) 14.4 1 3.07 (0.08-17.13) 6.9
leukemia 6 3.65 (1.34-7.94) 9.2 - - -
stomach mouth, pharynx 6 0.97 (0.36-2.12) −0.1 1 0.70 (0.02-3.91) −0.4
oesophagus 8 2.07 (0.90-4.09) 3.3 1 1.56 (0.04-8.71) 0.4
colon, rectum 68 1.68 (1.30-2.13) 21.8 40 1.86 (1.33-2.54) 18.9
pancreas 17 2.09 (1.22-3.34) 7.0 13 2.24 (1.19-3.83) 7.3
larynx 3 1.18 (0.24-3.43) 0.4 - - -
bronchus, lung 33 1.15 (0.79-1.62) 3.5 9 1.34 (0.61-2.54) 2.3
kidney 19 2.26 (1.36-3.53) 8.4 6 1.66 (0.61-3.62) 2.4
urinary tract 1 0.65 (0.02-3.64) −0.4 - - -
urinary bladder 17 0.87 (0.51-1.39) −2.0 3 0.69 (0.14-2.01) −1.4
leukemia 11 1.80 (0.90-3.22) 3.9 6 1.88 (0.69-4.09) 2.9
colon, rectum mouth, pharynx 56 1.48 (1.12-1.92) 2.5 13 1.50 (0.80-2.56) 0.7
oesophagus 31 1.33 (0.91-1.89) 1.1 8 2.07 (0.89-4.08) 0.7
stomach 73 1.11 (0.87-1.40) 1.0 45 1.31 (0.96-1.75) 1.8
pancreas 43 0.92 (0.66-1.23) −0.5 44 1.30 (0.94-1.74) 1.7
larynx 15 0.97 (0.54-1.60) −0.1 - - -
bronchus, lung 210 1.26 (1.09-1.44) 5.8 60 1.47 (1.12-1.89) 3.3
kidney 85 1.71 (1.37-2.12) 4.8 36 1.67 (1.17-2.31) 2.5
urinary tract 12 1.40 (0.72-2.44) 0.5 7 1.86 (0.75-3.84) 0.6
urinary bladder 148 1.34 (1.13-1.58) 5.1 38 1.49 (1.06-2.05) 2.1
leukemia 59 1.71 (1.3-2.21) 3.3 32 1.73 (1.18-2.44) 2.3
pancreas mouth, pharynx 1 0.47 (0.01-2.59) −2.7 1 1.77 (0.04-9.87) 1.1
oesophagus 1 0.80 (0.02-4.48) −0.6 - - -
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Table 2 Relative and absolute risks of subsequent tobacco-related primary cancer according to type of first tobacco-
related primary cancer and sex (Bavaria; 2002–2008) (Continued)
stomach 9 2.91 (1.33-5.52) 14.1 7 3.60 (1.45-7.42) 12.7
colon, rectum 16 1.41 (0.81-2.29) 11.1 12 1.63 (0.84-2.84) 11.6
larynx 3 3.57 (0.74-10.43) 5.2 - - -
bronchus, lung 10 1.18 (0.57-2.18) 3.7 3 1.12 (0.23-3.26) 0.8
kidney 4 1.58 (0.43-4.04) 3.5 4 2.88 (0.79-7.39) 6.6
urinary bladder 7 1.36 (0.55-2.81) 4.5 - - -
leukemia 1 0.61 (0.02-3.40) −1.5 2 1.82 (0.22-6.58) 2.26
larynx mouth, pharynx 33 8.83 (6.08-12.41) 41.9 3 26.52 (5.47-77.51) 34.8
oesophagus 18 8.92 (5.28-14.09) 22.9 1 23.53 (0.60-131.09) 11.6
stomach 5 1.10 (0.36-2.57) 0.7 1 3.95 (0.10-22.03) 9.0
colon, rectum 18 1.05 (0.63-1.67) 1.3 - - -
pancreas 9 2.61 (1.19-4.95) 7.9 1 3.74 (0.09-20.82) 8.8
bronchus, lung 69 5.37 (4.18-6.80) 80.4 9 18.83 (8.61-35.75) 102.9
kidney 6 1.53 (0.56-3.32) 3.0 - - -
urinary tract 1 1.71 (0.04-9.53) 0.6 - - -
urinary bladder 10 1.31 (0.63-2.41) 3.4 1 4.79 (0.12-26.68) 9.6
leukemia 2 0.82 (0.10-2.97) −0.6 - - -
bronchus, lung mouth, pharynx 42 3.48 (2.51-4.71) 13.1 10 6.46 (3.10-11.88) 7.5
oesophagus 20 2.83 (1.73-4.37) 5.6 3 4.84 (1.00-14.14) 2.1
stomach 28 1.60 (1.06-2.31) 4.6 12 2.88 (1.49-5.03) 6.9
colon, rectum 71 1.10 (0.86-1.39) 2.8 17 1.02 (0.59-1.63) 0.3
pancreas 19 1.47 (0.89-2.30) 2.7 10 2.31 (1.11-4.24) 5.0
larynx 37 7.78 (5.48-10.72) 14.1 1 4.94 (0.12-27.50) 0.7
kidney 32 2.21 (1.51-3.12) 7.6 13 3.94 (2.10-6.74) 8.6
urinary tract 6 2.62 (0.96-5.71) 1.6 3 5.93 (1.22-17.33) 2.2
urinary bladder 63 2.15 (1.65-2.75) 14.7 9 2.69 (1.23-5.11) 5.0
leukemia 16 1.72 (0.98-2.80) 2.9 3 1.21 (0.25-3.53) 0.5
kidney mouth, pharynx 10 1.11 (0.53-2.03) 0.5 1 0.62 (0.02-3.44) −0.5
oesophagus 4 0.76 (0.21-1.95) −0.7 - - -
stomach 15 1.14 (0.64-1.89) 1.1 5 0.90 (0.29-2.09) −0.5
colon, rectum 51 1.06 (0.79-1.39) 1.5 25 1.17 (0.76-1.73) 3.2
pancreas 9 0.93 (0.42-1.76) −0.4 5 0.87 (0.28-2.02) −0.7
larynx 3 0.86 (0.18-2.50) −0.3 1 5.08 (0.13-28.28) 0.7
bronchus, lung 54 1.51 (1.13-1.97) 10.1 16 2.06 (1.18-3.34) 7.1
urinary tract 3 1.75 (0.36-5.12) 0.7 3 4.47 (0.92-13.07) 2.0
urinary bladder 51 2.31 (1.72-3.03) 16.1 10 2.29 (1.10-4.21) 4.9
leukemia 12 1.72 (0.89-3.00) 2.8 2 0.63 (0.08-2.28) −1.0
urinary tract oesophagus 1 1.64 (0.04-9.15) 2.0 - - -
stomach 2 1.05 (0.13-3.80) 0.5 - - -
colon, rectum 12 1.84 (0.95-3.21) 28.5 4 1.21 (0.33-3.10) 4.9
pancreas 3 2.28 (0.47-6.66) 8.8 3 3.35 (0.69-9.78) 14.7
bronchus, lung 9 1.96 (0.89-3.72) 22.9 4 3.82 (1.04-9.77) 20.7
kidney 4 2.97 (0.81-7.60) 13.8 - - -
urinary bladder 5 1.58 (0.51-3.68) 9.5 12 17.84 (9.22-31.15) 79.3
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Table 3 Groups of tobacco-related cancer sites with mutually significantly increased risk of subsequent primary cancer
valid for at least one sex and split into pairs (Bavaria; 2002–2008; for each pair, the respective identified sex is given
as well as known shared risk factors; data sources, [17-21])
Group
Pair of cancer types with mutually
significantly elevated risk of subsequent
primary cancer
Sex Shared risk factors in addition
to tobacco smoking
1 mouth/pharynx – oesophagus m,f alcohol consumption, low fruit and vegetable intake,
low socioeconomic status
mouth/pharynx – larynx m,f alcohol consumption, low fruit and vegetable intake
mouth/pharynx – lung/bronchus m,f low fruit and vegetable intake
oesophagus – larynx m alcohol consumption, low fruit and vegetable intake
larynx – lung/bronchus m low fruit and vegetable intake
lung/bronchus – oesophagus m low fruit and vegetable intake
2 lung/bronchus – kidney m,f -
kidney – bladder m,f -
bladder – lung/bronchus m,f -
3 bladder – lung/bronchus m,f -
lung/bronchus – urinary tract f -
urinary tract – bladder f ionizing radiation, heavy use of phenacetin-containing analgesic
4 mouth/pharynx – colon/rectum m alcohol consumption, low fruit and vegetable intake
5 stomach – pancreas m,f obesity
Table 2 Relative and absolute risks of subsequent tobacco-related primary cancer according to type of first tobacco-
related primary cancer and sex (Bavaria; 2002–2008) (Continued)
leukemia 2 2.03 (0.25-7.32) 5.3 - - -
urinary bladder mouth, pharynx 25 1.41 (0.91-2.08) 2.0 3 1.63 (0.34-4.77) 1.0
oesophagus 12 1.05 (0.54-1.83) 0.2 3 3.60 (0.74-10.53) 1.8
stomach 41 1.13 (0.81-1.53) 1.3 16 2.10 (1.20-3.40) 6.8
colon, rectum 144 1.16 (0.98-1.36) 5.5 26 0.95 (0.62-1.39) −1.2
pancreas 31 1.24 (0.84-1.75) 1.7 6 0.80 (0.29-1.74) −1.2
larynx 4 0.53 (0.15-1.36) −1.0 - - -
bronchus, lung 187 2.16 (1.86-2.49) 27.9 25 2.87 (1.85-4.23) 13.3
kidney 77 3.04 (2.40-3.80) 14.4 12 2.56 (1.32-4.48) 6.0
urinary tract 7 1.47 (0.59-3.03) 0.6 6 7.26 (2.66-15.79) 4.2
leukemia 30 1.59 (1.07-2.27) 3.1 8 1.96 (0.85-3.87) 3.2
leukemia mouth, pharynx 3 0.73 (0.15-2.13) −1.2 2 2.42 (0.29-8.73) 1.8
oesophagus 5 2.10 (0.68-4.89) 2.9 - - -
stomach 9 1.43 (0.66-2.72) 3.0 4 1.50 (0.41-3.84) 2.0
colon, rectum 27 1.19 (0.79-1.74) 4.8 14 1.37 (0.75-2.30) 5.8
pancreas 6 1.32 (0.48-2.87) 1.6 4 1.48 (0.40-3.78) 2.0
larynx 1 0.63 (0.02-3.48) −0.7 - - -
bronchus, lung 27 1.63 (1.08-2.38) 11.5 7 1.83 (0.74-3.77) 4.8
kidney 7 1.40 (0.56-2.89) 2.2 - - -
urinary tract 3 3.68 (0.76-10.76) 2.4 - - -
urinary bladder 11 1.05 (0.52-1.87) 0.5 4 1.94 (0.53-4.97) 3.0
O, number of observed cases; SIR, standardized incidence ratio; 95% CI, 95% confidence interval; EAR, excess absolute risk per 10,000; bold type, SIR significantly
different from one.
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Table 4 Frequency distribution of treatment according to site of first primary cancer (Bavaria; 2002–2008; DCO cases excluded; treatments are grouped so






















mouth, pharynx 2,844 430 78 380 1,762 82 422 1,016 28 1,192 484 219 1,391 10,328
(28%) (4%) (1%) (4%) (17%) (1%) (4%) (10%) (0%) (12%) (5%) (2%) (14%) (100%)
oesophagus 764 203 232 350 46 167 154 495 66 232 271 204 985 4,169
(18%) (5%) (6%) (8%) (1%) (4%) (4%) (12%) (2%) (6%) (7%) (5%) (24%) (100%)
stomach 6,519 51 751 160 39 1,192 249 65 92 274 234 677 3,041 13,344
(49%) (0%) (6%) (1%) (0%) (9%) (2%) (1%) (1%) (2%) (2%) (5%) (23%) (100%)
colon, rectum 29,367 223 342 567 656 7,861 2,013 623 56 3,927 1,855 783 5,189 53,462
(55%) (0%) (1%) (1%) (1%) (15%) (4%) (1%) (0%) (7%) (4%) (2%) (10%) (100%)
pancreas 1,837 40 1,430 232 39 1,134 167 159 198 185 305 393 1,946 8,065
(23%) (1%) (18%) (3%) (1%) (14%) (2%) (2%) (3%) (2%) (4%) (5%) (24%) (100%)
larynx 1,359 121 21 41 357 21 69 129 6 228 76 64 397 2,889
(47%) (4%) (1%) (1%) (12%) (1%) (2%) (5%) (0%) (8%) (3%) (2%) (14%) (100%)
bronchus, lung 4,538 1,876 4,506 579 825 1,294 226 3,072 640 957 1,588 1,428 5,617 27,146
(17%) (7%) (17%) (2%) (3%) (5%) (1%) (11%) (2%) (4%) (6%) (5%) (21%) (100%)
kidney 9,013 46 30 55 140 135 165 3 16 35 238 93 875 10,844
(83%) (0%) (0%) (1%) (1%) (1%) (2%) (0%) (0%) (0%) (2%) (1%) (8%) (100%)
urinary tract 1,119 3 7 7 41 148 29 _ 2 27 15 23 149 1,570
(71%) (0%) (0%) (0%) (3%) (9%) (2%) (0%) (2%) (1%) (2%) (10%) (100%)
urinary bladder 13,306 13 17 16 219 1,562 467 10 4 234 172 206 2,226 18,452
(72%) (0%) (0%) (0%) (1%) (9%) (3%) (0%) (0%) (1%) (1%) (1%) (12%) (100%)
leukemia 99 84 1,743 224 5 37 5 219 633 8 188 770 2,451 6,466
(2%) (1%) (27%) (4%) (0%) (1%) (0%) (3%) (10%) (0%) (3%) (12%) (38%) (100%)
surg, surgery; radio, radiotherapy; chemo, chemotherapy; further details about ‘other therapy’ are not available; other treatment, other combinations of therapies; bold type, the three most frequent treatments of each

















Figure 1 Comparison between own results and SEER results.
Groups of tobacco-related malignancies with mutually and
significantly increased risk of subsequent malignancy according to
sex. Significant associations found both by SEER and in Bavaria are
highlighted in black; associations with grey arrows are only found
either in SEER results (solid arrows) or in own results (dashed
arrows).
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http://www.biomedcentral.com/1471-2407/12/250significantly SIRs were only found in three dyads: (1)
mouth/pharynx and oesophagus; (2) mouth/pharynx and
larynx; (3) mouth/pharynx and lung/bronchus.
Group 2 was identified in both sexes and included pri-
mary cancers in the lung/bronchus, in the kidneys
(C64), and in the urinary bladder (C67 +D09.0 +D41.4).
Similarly, group 3 contained the dyad of urinary blad-
der and lung/bronchus, but in addition also the dyads
lung/bronchus with the urinary tract (C65-C66, C68),
and the urinary tract with the urinary bladder. However,
this group was only found to exist among women.
Group 4 and 5, respectively, incorporate only two
types of cancer each: group 4, malignancies in the
mouth/pharynx and colon/rectum (C18-C21), respect-
ively; group 5, malignancies in the stomach (C16) and
pancreas (C25). Both groups were identified in men.
Among women, however, only group 5 was found to
exist.
In Table 4, the frequency distribution of treatment in
Bavaria is given according to site of first primary cancer
as seen in our data. The most frequent treatment was
surgery except in leukemia which is predominantly trea-
ted by chemotherapy.
Discussion
The objective of this study was to find out if the shared
risk factor tobacco smoking leads to a significantly
increased risk of TRSPC among persons with TRFPC
compared to the general population. Furthermore, we
tried to gain new insights into the possible etiology of
the evaluated cancer types.
Comparisons between our own results and results
from other research groups can be difficult because of
different employed classifications of diagnosis groups.
Hence, a one-to-one comparison is not always possible.
All studies discussed in this section were registry-based
and gave risk estimates for all subsequent cancers.
The SEER Program (Surveillance, Epidemiology and
End Results Program) is the only available study that has
analysed the risk of subsequent cancer in more than 50
cancer types in adults, that is based on a long observa-
tion period (1973–2000), and on a large population of
more than 2 million cancer survivors [22]. With regard
to tobacco-related malignancies, the results of SEER [17-
21,23] are summarized in Figure 1 by identifying groups
with mutually and significantly increased risk of TRSPC
on the one hand, and by comparison with our own
results on the other hand.
In contrast to our study, colon and rectum cancer
were separately evaluated, and lip cancer was excluded
from the evaluation of first primary cancers in the oral
cavity/pharynx, respectively, in the SEER study. How-
ever, in subsequent malignancies, the SEER study pro-
vided results on cancer of the oral cavity/pharynxincluding lip cancer (as was done in our study). Conse-
quently, with respect to corresponding results, we can
only perform a crude comparison in the aforementioned
two cancer sites.
In contrast to our results, based on the SEER results, a
group of malignancies can be identified in both genders
consisting of the oral cavity/pharynx, oesophagus, lung/
bronchus, and larynx. In addition to tobacco smoking,
low fruit and vegetable intake is considered to be a
shared risk factor for these cancer types (Table 3).
Tobacco smoking accounts for about 60% of all lung/
bronchus cancer cases in women and for 90% of all
Table 5 Cancer treatment according to site of first primary cancer in Germany (Munich Cancer Registry [1977–1993] unless mentioned otherwise; data sources,
[32,33])









Surg + radio Surg+ chemo Surg+
other
therapy






mouth 32% 13% 3% 32% 1% / 13% 6% / 100%
oropharynx 10% 21% 2% 37% 1% / 19% 12% / 100%
oesophagus 33% 21% / 12% / / 20% / 14% 100%
stomach 90% / / / / / / / 10% 100%
colon 92% / / / 8% / / / / 100%
rectum 80% / / 9% 5% / / 7% / 100%
pancreas 100% / / / / / / / / 100%
larynx 38% 20% / 37% / / / 5% / 100%
non-small cell trachea/bronchus/
lung
40% 25% 6% / / / / / 30% 100%
small cell trachea/bronchus/lung 6% 7% 46% / / / / / 41% 100%
kidney 100%
12
/ / / / / / / / 100%
urinary bladder 100%3 / / / / / / / / 100%
leukemia / / 100%
14
/ / / / / / 100%
surg, surgery; radio, radiotherapy; chemo, chemotherapy; bold type, the three most frequent treatments in each cancer site; 1treatment recommended by Deutsche Krebsgesellschaft (2008); 2treatment with curative
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http://www.biomedcentral.com/1471-2407/12/250lung/bronchus cancer cases in men [24]. The relative
risk of lung/bronchus cancer among current smokers is
33 among men and 20 among women compared with
lifelong non-smokers [25]. In our study, the diagnosis
group of lung/bronchus showed a mutually significantly
increased risk with almost every other diagnosis group.
Therefore, with the exception of pancreatic cancer,
stomach cancer, colorectal cancer, and leukemia, tobacco
smoking can be confirmed as a shared risk factor in all
tobacco-related cancer types considered in this study.
The lack of mutually significantly increased relative risks
between cancer in the oesophagus, larynx and lung/
bronchus among women in our study might be due to
insufficient sample size.
In both sexes, the group of urinary bladder, kidney and
lung/bronchus was only found based on our own results,
because in the SEER study, no mutually and significantly
increased risk of SPC between the kidneys and the lung/
bronchus was identified. However, tobacco smoking is
the only known shared risk factor of these cancer types
(Table 3). According to SEER, tobacco smoking accounts
for about 50-65% of cases of urinary bladder cancer
among men and for 20-30% of cases among women,
respectively [17]. Furthermore, the hazard ratio of devel-
oping bladder cancer is 3.9 (95% CI, 3.5-4.4) among
current male smokers and 4.7 (95% CI, 3.7-5.8) among
current female smokers compared to never smokers [26].
The lack of a mutually significantly elevated risk of
SPC between the urinary tract and bladder in men with
regard to our own results may possibly be explained
by the fact that in former decades, the misuse of
phenacetin-containing analgesics (Table 3), a known risk
factor for urinary cancer, was more common in Euro-
pean women than in men [27]. This fact might also ex-
plain the larger SIR with respect to these cancer sites in
women compared to men (Table 2).
According to both the results of SEER and of the Bav-
arian Cancer Registry, the colon was a member of a
group with increased risk of TRSPC in men but not in
women. With regard to the results of SEER, the colon
was a member of a dyad with the urinary tract, whereas
in our study the colon/rectum formed a dyad with the
oral cavity/pharynx. Based on the results shown in Fig-
ure 1, smoking does not appear to be a major risk factor
in colorectal cancer. According to published reports, the
multivariate-adjusted rate ratio of colorectal cancer mor-
tality for current compared with never smokers is 1.3
(95% CI, 1.2-1.5) among men and 1.4 (95% CI, 1.3-1.6)
among women [28]. Cigarette smoking accounts for only
about 12% of colorectal cancer deaths [28]. Moreover, it
is surprising that the dyad colon and oral cavity/pharynx
was not found in the SEER study because of the add-
itional shared risk factor low fruit and vegetable intake
(Table 3) which may hint to differences between bothcountries with respect to the extent of this issue [29,30].
However, in our study, but not in the SEER study, the
rectum was an additional member of this diagnosis
group which somewhat limits the interpretation of this
comparison.
Among both men and women, an isolated dyad was
identified consisting of primary cancers in the stomach
and pancreas which was found only in Bavaria. A mutu-
ally significantly increased risk of subsequent maligancy
between these two cancer types was found in our study.
However, neither in our own study nor in the SEER
study was any of these two cancer types included in any
other significant association. Furthermore, tobacco
smoking is not considered to be a strong risk factor for
stomach cancer. Therefore, tobacco smoking was not
confirmed as a main risk factor in stomach and pancreas
cancer. This finding, however, does not rule out a pos-
sible weaker etiological association of these two cancer
types with tobacco smoking. The second known shared
risk factor obesity (Table 3) may possibly help to explain
this significant association. This dyad, however, was not
observed in the SEER study although obesity appears to
be a larger problem in the United States than in Europe
[29,30]. Furthermore, it should be noted that pancreatic
cancer has a very unfavourable prognosis which in turn
leads to small absolute numbers of subsequent cancers.
Among persons with pancreatic cancer, the relative 5-
year survival rate in Germany is only 5-7% among men
and 3-8% among women [24]. Consequently, the preci-
sion of the respective risk estimates was very limited.
Based on Figure 1, the diagnosis group of leukemia is
the only cancer type which was not included in any group
of mutually increased risk of TRSPC. In line with this find-
ing, only a weak etiologic association with tobacco smok-
ing has been reported for this malignancy [23].
In contrast to our results, SEER identified several sig-
nificantly reduced risks of TRSPC. According to SEER, a
significantly decreased risk of SPC in the lung/bronchus
and in the urinary bladder after pancreatic cancer was
identified in men. The explanation used by SEER is that
pancreatic cancer has a very poor prognosis which in
turn prevents the development of larger numbers
of TRSPC. However, we neither found significantly
decreased nor increased risks with regard to the afore-
mentioned tumour sequences in our results, although
tobacco smoking is a confirmed risk factor for all three
cancer types.
The most surprising SEER result, however, was a sig-
nificantly reduced risk of SPC in the oral cavity/pharynx
and in the lung/bronchus, respectively, after kidney can-
cer in men. This is surprising because tobacco smoking
is assumed to be a shared risk factor of these three can-
cer types. By contrast, our results showed a slightly
increased risk of SPC in the oral cavity/pharynx in men,
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women: SIR, 2.06) of subsequent lung cancer, respect-
ively, after kidney cancer.
Furthermore, in contrast to our results, significantly
decreased risks of SPC in the stomach (SIR, 0.8; 95% CI
[SIR], 0.7-1.0) and colorectum (SIR, 0.7; 95% CI[SIR],
0.6-0.9) were identified in men with lung cancer in Fin-
land during the period 1953–1995 [31]. In women, the
respective risks were also (but not significantly)
decreased (stomach cancer: SIR, 0.7; 95% CI[SIR] 0.3-
1.4); colorectal cancer: SIR, 0.9; 95% CI[SIR], 0.5-1.6). In
Finland, lung cancer has typically been a cancer type of
the lower social classes in men whereas it was more fre-
quent in the higher social classes in women at least until
the mid-1980s [31]. Moreover, in Finland, the highest in-
cidence of stomach cancer has been found in the poorer
social strata, whereas colorectal cancer has typically been
a cancer of the affluent classes [31]. These findings
might possibly explain the observed significantly reduced
risk of colorectal cancer among male patients, the
decreased risk of stomach cancer among female patients,
and the slightly decreased risk of colorectal cancer
among female patients. An additional explanation of
decreased risks might be the unfavourable prognosis of
lung cancer (similar to pancreatic cancer) which in turn
prevents the development of larger numbers of TRSPC
in diseased persons.
Radiotherapy was administered in at least 42% of per-
sons with FPC in the mouth/pharynx (Table 4). Further-
more, a considerable proportion of patients with cancer
in the oesophagus (at least 24%), larynx (at least 29%),
and lung/bronchus (at least 25%) was also treated with
radiotherapy. Therefore, radiotherapy might have con-
tributed to the significantly increased risk of TRSPC in
these patients.
Since chemotherapy was applied in a relatively high
proportion of persons with FPC in the mouth/pharynx
(at least 23%), oesophagus (at least 29%), stomach (at
least 18%), colon/rectum (at least 24%), pancreas (at
least 39%), lung/bronchus (at least 39%), and leukemia
(at least 41%), it might also have contributed to the sig-
nificantly increased risk of TRSPC.
In comparison with our results, surgery was generally
administered in a higher proportion of persons accord-
ing to published German studies [32] (Table 5). These
discrepancies may be due to the different observation
periods. During the last decade, there seems to have
been a tendency to conduct more clinical studies com-
pared to former decades. This may have lead to a
decreased proportion of exclusive surgical treatment and
to an increased proportion of other treatments, which in
turn may help to explain the observed differences with
respect to treatment of cancer in the stomach, colon/
rectum, pancreas, and urinary bladder.Moreover, kidney cancer was most frequently treated
with surgery alone, and leukemia was predominantly
treated with chemotherapy (Table 4). Consequently, ad-
herence to the recommendations of the Deutsche Krebs-
gesellschaft can be concluded with respect to the
aforementioned two cancer types [33].
In summary, despite some differences, the main results
of our study are confirmed by published international
studies. With the exception of pancreatic cancer, stom-
ach cancer, colorectal cancer, and leukemia, we were
able to confirm the hypothesis of a significantly
increased risk of TRSPC among persons with TRFPC
compared to the general population. Hence, the afore-
mentioned finding was most prominent in cancer types
which are known to be strongly related to tobacco
smoking.
The smoking prevalence of adults aged between 25
and 69 years in Germany has decreased in men and
increased in women since 1986, but in the year 2006,
the proportion of smokers among men (36%) was still
higher than among women (28%) [34]. Due to the com-
parison with the general population in which the pro-
portion of female smokers, and thus the risk of
developing a tobacco-related cancer, is smaller compared
to the study population, the relative risk of TRSPC
among women with TRFPC compared to the female
general population may be higher than that among men.
Therefore, the aforementioned sex difference with re-
spect to smoking prevalence might be the cause of
higher SIR`s among women than among men in several
tobacco-related cancer sites. However, there are known
sex differences with regard to the attributable fractions
of tobacco smoking in tobacco-related cancers. There-
fore, this explanation is difficult to verify without know-
ledge of the individual smoking status in our study
population.
The importance of smoking cessation programs for
cancer patients with a TRFPC is underlined by results of
a study of the National Cancer Institute (NCI) in Mary-
land revealing that 12 out of 55 (22%) lung cancer
patients continued to smoke for at least six months after
the diagnosis of lung cancer [35]. In view of the long-
term reduction of tobacco-related cancer incidence, a
rigid tobacco control policy should be advanced in Ger-
many to further reduce the smoking rate [36]. The effi-
cacy of a rigid tobacco control policy has previously
been confirmed in all age groups [37]. Furthermore, lung
cancer patients who stop smoking after the diagnosis of
cancer show a steadily decreasing risk of TRSPC over
time [35]. Since the relative 5-year survival rate of
patients with cancer of the oesophagus, pancreas, and
lung is below 23% in Germany [24], the efficacy of a
rigid tobbacco control policy especially with regard to
these cancer types would be considerable. By contrast,
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bladder have a better prognosis with 5-year survival rates
above 64%.
Limitations of our study
Despite the large underlying data base obtained from a
population-based cancer registry with an extensive
catchment area, a number of limitations apply.
Firstly, no data on tobacco smoking among cancer
patients was available. Consequently, an unknown degree
of confounding can be assumed with regard to the
obtained risk estimates which should be expected to dif-
fer considerably between smokers and non-smokers.
Secondly, only crude data about the applied therapies
was available. For this reason and because the numbers
of cases in each treatment stratum were too small to
permit the calculation of meaningful results, we did not
evaluate the risk of SPC stratified by treatment in order
to evaluate possible risk differences. Likewise, calculation
of the risk of SPC according to different histological
tumour types was not possible due to insufficient num-
bers of events. Therefore, future studies should evaluate
the risk of TRSPC according to different treatments and
histological tumour types, respectively.
Thirdly, registration completeness of tobacco-related
cancer cases was intermittingly below 90% in some parts
of Bavaria during the observation period. In the year
2002, for example, the registration completeness among
different diagnosis groups ranged between 67 and 99%.
In general, a registration completeness of at least 90% is
required to obtain valid results from population-based
cancer registries [38]. This deficiency, however, was com-
pensated in part by the employed standardisation of risk
estimates based on the Bavarian general population, thus
limiting the extent of severe risk underestimation. There-
fore, the degree of confounding caused by this deficiency
appears to be acceptable.
Fourthly, the overall duration of the present study was
only seven years. However, Bavaria is the federal state
(Bundesland) with the second largest population in Ger-
many. Therefore, we consider the overall study population
of 197,517 cancer patients and 331,759 person-years at
risk to be sufficient for valid analyses. Furthermore,
tobacco-related carcinogens can be assumed to have acted
for several decades in many smokers prior to the diagnosis
of TRFPC [39]. Therefore, in many smokers, TRSPC can
be expected to develop within a relatively short time span
(less than 10 years) after TRFPC. Consequently, we were
able to evaluate the short-term risk of tobacco-related
SPC according to 11 sites of first primary cancer.
Conclusions
In conclusion, with the exception of pancreatic cancer,
stomach cancer, colorectal cancer, and leukemia, thehypothesis of a significantly increased risk of TRSPC
among persons with TRFPC compared to the general
population was confirmed in all cancer types considered
in this study. Furthermore, with regard to these cancer
types, smoking was confirmed as a shared risk factor.
Consequently, our results confirm the dramatic conse-
quences of tobacco smoking with regard to tobacco-
related SPC. The results underline the importance of
smoking cessation (preferably within special programmes)
particularly among smokers with tobacco-related FPC in
order to reduce the risk of multiple cancers. Furthermore,
the results of this study illustrate the importance of
follow-up examinations in smokers with tobacco-related
FPC who continue to smoke in order to detect subsequent
malignancies at an early stage. However, the calculation of
the optimum duration and intensity of follow-up care
among these patients requires further research.
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